Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its financial results for the first two quarters of 2024:
MSK’s financial performance for the first two quarters of 2024 continued to demonstrate positive financial results, with an excess of operating revenue over expenses of $55.4 million and an operating cash flow margin of 5.6%. These operating results are attributed to expanding patient access and clinical growth, increased research and philanthropic activity, and effective expense management.
Patient revenues increased by 12.1% compared to the first two quarters of 2023, while total operating expenses rose by just 9.4% to support additional patient activity.
MSK continues to execute a fiscal strategy grounded in our ongoing initiatives to expand patient access, drive efficiency, and manage expenses in pursuit of continued financial stability.
For more information, please see instructions to access our financial disclosure report available at https://www.dacbond.com/ or https://www.mskcc.org/public-notices/financial-information.